drugset / Trial / NCT05182697
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
Recruiting
60 enrolled
Neurothera Labs Inc.
Negev Autism Center Soroka University Medical Center · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)
Timeline
- Start
- 2024-02-21
- Primary completion
- 2026-05
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palmidrol | Small molecule | 400 mg | Oral |
| Comparator | CBD | Unknown | — | Oral |